Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02231164 · ClinicalTrials.gov registry record · Phase 3
LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Terminated
- Registry status
- Phase 3
- Development phase
- 12
- Enrollment target
NCT02231164 is a Phase 3 study that was terminated before completion, run by Boehringer Ingelheim. The registered enrollment target is 12 participants.
The verdict
NCT02231164, a Phase 3 study, was terminated before completion, sponsored by Boehringer Ingelheim.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 12 participants
- Enrollment target
Study Summary
The present trial will investigate the efficacy and safety of nintedanib in combination with docetaxel as compared to placebo in combination with docetaxel in patients with stage IIIB/IV or recurrent NSCLC of adenocarcinoma histology after failure of first-line platinum-based chemotherapy.
Interventions
- DRUG placebo
- DRUG docetaxel
- DRUG nintedanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2014-10-14 |
| Est. Completion | 2015-12-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02231164
The ClinicalTrials.gov registry entry for NCT02231164 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT02231164 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02231164 about?
NCT02231164 is a clinical study titled "LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research". The present trial will investigate the efficacy and safety of nintedanib in combination with docetaxel as compared to placebo in combination with docetaxel in patients with stage IIIB/IV or recurrent NSCLC of adenocarcinoma histology after failure of first-line platinum-based chemotherapy.
What is the current status of trial NCT02231164?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 12 participants. The study started on 2014-10-14. Estimated completion is 2015-12-24.
What interventions are being tested in trial NCT02231164?
The interventions under investigation include: placebo (DRUG), docetaxel (DRUG), nintedanib (DRUG).
Who is sponsoring clinical trial NCT02231164?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.